1-1 of 1 results for subject:Pfizer
Librarians' tools
- Search time
- 2.435 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what data his Department holds on the effectiveness of the (a) Pfizer, (b) AstraZeneca and (c) Moderna covid-19 vaccinations at reducing transmission of covid-19.
To ask the Secretary of State for Health and Social Care, what data his Department holds on the effectiveness of the (a) Pfizer, (b) AstraZeneca and (c) Moderna covid-19 vaccinations at reducing transmission of covid-19.
Public Health England (PHE) publishes weekly COVID-19 vaccine surveillance reports which include the latest evidence on vaccine effectiveness against different outcomes. The following table shows the latest summary of evidence on vaccine effectiveness against different outcomes, including transmission, for Pfizer/BioNTech and University of Oxford/AstraZeneca as of 1 July.
Outcome | Vaccine Effectiveness | |||
Pfizer/BioNTech | Oxford/AstraZeneca | |||
1 dose | 2 doses | 1 dose | 2 doses | |
Symptomatic disease | 55-70%* | 85-95%* | 55-70%* | 70-85%** |
Hospitalisation | 75-85%* | 90-99%** | 75-85%* | 80-99%*** |
Mortality | 70-80%** | 95-99%** | 75-85%** | 75-99%*** |
Infection | 55-70%** | 70-90%*** | 60-70%*** | No data |
Transmission (secondary cases)^ | 45-50%*** | No data | 35-50%*** | No data |
Source: Table 3 https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report
Notes:
- *High Confidence - Evidence from multiple studies which is consistent and comprehensive
- **Medium Confidence - Evidence is emerging from a limited number of studies or with a moderately level of uncertainty
- ***Low Confidence - Little evidence is available at present and results are inconclusive
- ^effectiveness in reducing symptomatic secondary cases in households of a symptomatic index case
PHE plans to publish vaccine effectiveness data for Moderna when more evidence becomes available.